Document Detail


Upregulation of inducible nitric oxide synthase contributes to attenuated cutaneous vasodilation in essential hypertensive humans.
MedLine Citation:
PMID:  21931069     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Essential hypertension is a proinflammatory, proconstrictor disease coinciding with endothelial dysfunction and inward vessel remodeling. Using the skin circulation, our aim was to determine whether inducible NO synthase (iNOS) upregulation attenuates NO-dependent cutaneous vasodilation in hypertensive humans. We hypothesized that, with hypertension, localized iNOS inhibition would restore vasodilation in response to NO-dependent stimuli, and iNOS expression would be increased and phosphorylated vasodilator-stimulated phosphoprotein would be decreased. For, in vivo protocols, 4 intradermal microdialysis fibers were placed in 9 hypertensive and 10 normotensive men and women (systolic blood pressure: 146±4 versus 113±2 mm Hg; P<0.001). Microdialysis fibers served as control, iNOS inhibited (1400 W), neuronal NO synthase inhibited (N(ω)-propyl-l-arginine), and nonselective NOS inhibited (N(G)-nitro-l-arginine methyl ester). Cutaneous vascular conductance was calculated (percentage of sodium nitroprusside) during standardized local heating (42°C) and acetylcholine dose-response protocols (0.01, 0.10, 1.00, 5.00, 10.00, 50.00, 100.00 mmol/L). The NO-dependent local heating response was attenuated at control (95±2% versus 76±2% cutaneous vascular conductance; P<0.05) and neuronal NO synthase-inhibited sites (94±4% versus 77±3% cutaneous vascular conductance; P<0.01) in hypertensives. iNOS inhibition augmented the NO-dependent local heating response (93±2% versus 89±10% cutaneous vascular conductance). Acetylcholine-induced vasodilation was attenuated in control sites at doses ≥0.1 mmol/L of acetylcholine in hypertensives and was restored with iNOS inhibition (0.1 mmol/L, P<0.05; 1, 5, and 10 mmol/L, P<0.001; 50 and 100 mmol/L, P<0.01). In vitro iNOS expression was increased (P=0.006) and phosphorylated vasodilator-stimulated phosphoprotein was decreased in skin from hypertensive humans (P=0.04). These data suggest that iNOS is upregulated in essential hypertensive humans and contributes to reduced NO-dependent cutaneous vasodilation.
Authors:
Caroline J Smith; Lakshmi Santhanam; Rebecca S Bruning; Anna Stanhewicz; Dan E Berkowitz; Lacy A Holowatz
Related Documents :
23953399 - Tyrosine/tyrosinate fluorescence at 700mpa: a pressure unfolding study of chicken ovomu...
3434099 - Prognostic value of consecutive peripheral pressure registration after reconstructive p...
1261529 - Ultrasonic measurement of arterial blood pressure in conditioned thoroughbreds.
3257679 - Epidural spinal cord electrical stimulation improves microvascular blood flow in severe...
12608969 - Comparison of ankle-brachial pressure index measurements using an automated oscillometr...
2258789 - Pseudohypertension in hypertensive patients on multiple drug therapy.
9740629 - Relation between coronary artery disease, aortic stiffness, and left ventricular struct...
11358929 - Gender differences in the regulation of blood pressure.
2413289 - Mechanism of the pulmonary vasoconstrictor action of digoxin in the dog.
Publication Detail:
Type:  Comparative Study; Journal Article; Research Support, N.I.H., Extramural     Date:  2011-09-19
Journal Detail:
Title:  Hypertension     Volume:  58     ISSN:  1524-4563     ISO Abbreviation:  Hypertension     Publication Date:  2011 Nov 
Date Detail:
Created Date:  2011-10-21     Completed Date:  2011-12-15     Revised Date:  2013-06-27    
Medline Journal Info:
Nlm Unique ID:  7906255     Medline TA:  Hypertension     Country:  United States    
Other Details:
Languages:  eng     Pagination:  935-42     Citation Subset:  IM    
Affiliation:
Department of Kinesiology, Pennsylvania State University, University Park, PA, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Administration, Cutaneous
Analysis of Variance
Blotting, Western
Case-Control Studies
Dose-Response Relationship, Drug
Female
Humans
Hypertension / enzymology*,  physiopathology
Laser-Doppler Flowmetry
Male
Middle Aged
NG-Nitroarginine Methyl Ester / pharmacology
Nitric Oxide Synthase Type II / metabolism*
Nitroprusside / pharmacology
Reference Values
Regional Blood Flow / drug effects
Skin / blood supply*,  drug effects
Up-Regulation / drug effects*
Vasodilation / drug effects,  physiology*
Grant Support
ID/Acronym/Agency:
R01 HL093238/HL/NHLBI NIH HHS; R01 HL093238-01/HL/NHLBI NIH HHS; R01 HL093238-02/HL/NHLBI NIH HHS; R01 HL093238-03/HL/NHLBI NIH HHS; R01-HL093238-02/HL/NHLBI NIH HHS; UL1 TR000127/TR/NCATS NIH HHS
Chemical
Reg. No./Substance:
15078-28-1/Nitroprusside; 50903-99-6/NG-Nitroarginine Methyl Ester; EC 1.14.13.39/Nitric Oxide Synthase Type II
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Helping patients decide: ten steps to better risk communication.
Next Document:  Evidence Implicating Peroxisome Proliferator-Activated Receptor-{gamma} in the Pathogenesis of Preec...